How does antibody-drug conjugate (ADC) therapy work for Breast Cancer

How Antibody-Drug Conjugate (ADC) Therapy Works for Breast Cancer

ADC therapy is a sophisticated approach that combines the precision of targeted therapy with the power of chemotherapy. Let me break down how it works:

The Basic Concept: A "Guided Missile" Approach

Think of an ADC as a guided missile system:

• The antibody = the guidance system that finds the target
• The drug = the powerful payload
• The linker = the connection that holds them together until the right moment

The antibody attaches to specific proteins on cancer cells, delivers chemotherapy directly to those cells, and then releases the drug inside them. This allows doctors to hit cancer cells with high doses of chemotherapy while sparing healthy cells.

How It Works Step-by-Step

1. Recognition & Binding The antibody portion recognizes and binds to a specific protein on breast cancer cells (like HER2 or TROP-2). This is why testing for these proteins is so important—the ADC only works if the cancer has the target protein.

2. Internalization Once attached, the cancer cell pulls the entire ADC complex inside itself, like swallowing the missile whole.

3. Drug Release Inside the cancer cell, the linker breaks down and releases the chemotherapy drug directly into the cell's interior, where it damages the cancer cell's DNA and causes cell death.

4. Selective Destruction Because healthy cells typically have fewer or none of these target proteins, they're largely spared from the chemotherapy damage.

Current ADC Options for Breast Cancer

According to NCCN Breast Cancer Guidelines, ADCs are now important treatment options:

HER2-Directed ADCs:

• Trastuzumab deruxtecan (Kadcyla) - FDA-approved for HER2-positive breast cancer
• Trastuzumab deruxtecan (Enhertu) - FDA-approved for HER2-low and HER2-positive breast cancer
• These are particularly valuable because they work even in HER2-low cancers (where HER2 levels are lower than traditional HER2-positive)

TROP-2-Directed ADCs:

• Sacituzumab govitecan (Trodelvy) - FDA-approved for triple-negative breast cancer (a more aggressive subtype)
• This targets TROP-2, a protein found on many breast cancers

Why ADCs Matter for Breast Cancer Treatment

According to the American Cancer Society, ADCs represent an important advancement because they:

• Deliver chemotherapy more precisely to cancer cells
• May cause fewer side effects than traditional chemotherapy (though they have their own side effect profile)
• Work for cancers that may not respond to other treatments
• Offer new options for advanced or metastatic breast cancer

Important Considerations

Testing Requirements: Your cancer must be tested for the specific protein the ADC targets (HER2, TROP-2, etc.). This is why biomarker testing is so critical in breast cancer care.

Side Effects: While ADCs are more targeted, they still cause side effects. Common ones include fatigue, nausea, and low blood cell counts. Some ADCs can affect the heart or lungs, so monitoring is important.

When They're Used: According to ASCO Guidelines, ADCs are used at various stages:

• Early-stage breast cancer (as adjuvant therapy after surgery)
• Advanced or metastatic breast cancer
• Sometimes as first-line treatment, sometimes after other therapies

Questions to Ask Your Oncologist

If ADC therapy is being considered for you:

1. "Does my cancer have the protein target for this ADC (HER2, TROP-2, etc.)?"
2. "Is an ADC recommended as part of my treatment plan, and why?"
3. "What are the specific side effects I should watch for, and how will you monitor me?"
4. "How will we know if the ADC is working, and how often will we check?"
5. "Are there other treatment options, and how does this ADC compare?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.